Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia

被引：13

作者：

Percival, Mary-Elizabeth M. ^{[1
,2
]}

Estey, Elihu H. ^{[1
,2
]}

机构：

[1] Univ Washington, Dept Med, Div Hematol, 825 Eastlake Ave E,MS CE3-300, Seattle, WA 98109 USA

[2] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA

来源：

CANCER | 2019年 / 125卷 / 18期

关键词：

acute myeloid leukemia (AML); clinical trials; complete remission; measurable residual disease (MRD); HEMATOPOIETIC-CELL TRANSPLANTATION; COMPLETE REMISSION; PROGNOSTIC IMPACT; GEMTUZUMAB OZOGAMICIN; RISK STRATIFICATION; DIRECTED THERAPY; IMPROVE OUTCOMES; FLOW-CYTOMETRY; AML; RELAPSE;

D O I：

10.1002/cncr.32354

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with acute myeloid leukemia (AML) who achieve a morphologic complete remission still can have measurable residual disease (MRD) detected by multiparametric flow cytometry, molecular methods, or cytogenetics. Such patients with MRD have a high risk of disease recurrence over a short timeframe, but optimal treatment strategies are unknown. Outcomes with conventional treatment, including allogeneic hematopoietic cell transplantation, are worse than those for patients without MRD. Herein, the authors review current strategies, including novel clinical trials, targeted toward patients with MRD.

引用

收藏

页码：3121 / 3130

页数：10

相关论文

共 49 条

[1] Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia [J].

Appelbaum, Frederick R. .

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2013, 26 (03) :279-284

[2] Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? [J].

Araki, Daisuke ;

Wood, Brent L. ;

Othus, Megan ;

Radich, Jerald P. ;

Halpern, Anna B. ;

Zhou, Yi ;

Mielcarek, Marco ;

Estey, Elihu H. ;

Appelbaum, Frederick R. ;

Walter, Roland B. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04) :329-+

[3] Time to repeal and replace response criteria for acute myeloid leukemia? [J].

Bloomfield, Clara Derber ;

Estey, Elihu ;

Pleyer, Lisa ;

Schuh, Andre C. ;

Stein, Eytan M. ;

Tallman, Martin S. ;

Wei, Andrew .

BLOOD REVIEWS, 2018, 32 (05) :416-425

[4] Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia [J].

Chen, Xueyan ;

Xie, Hu ;

Wood, Brent L. ;

Walter, Roland B. ;

Pagel, John M. ;

Becker, Pamela S. ;

Sandhu, Vicky K. ;

Abkowitz, Janis L. ;

Appelbaum, Frederick R. ;

Estey, Elihu H. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (11) :1258-+

[5] Persistence of Cytogenetic Abnormalities at Complete Remission After Induction in Patients With Acute Myeloid Leukemia: Prognostic Significance and the Potential Role of Allogeneic Stem-Cell Transplantation [J].

Chen, Yiming ;

Cortes, Jorge ;

Estrov, Zeev ;

Faderl, Stefan ;

Qiao, Wei ;

Abruzzo, Lynne ;

Garcia-Manero, Guillermo ;

Pierce, Sherry ;

Huang, Xuelin ;

Kebriaei, Partow ;

Kadia, Tapan ;

De Lima, Marcos ;

Kantarjian, Hagop ;

Ravandi, Farhad .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) :2507-2513

[6] Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia [J].

DiNardo, Courtney D. ;

Pratz, Keith ;

Pullarkat, Vinod ;

Jonas, Brian A. ;

Arellano, Martha ;

Becker, Pamela S. ;

Frankfurt, Olga ;

Konopleva, Marina ;

Wei, Andrew H. ;

Kantarjian, Hagop M. ;

Xu, Tu ;

Hong, Wan-Jen ;

Chyla, Brenda ;

Potluri, Jalaja ;

Pollyea, Daniel A. ;

Letai, Anthony .

BLOOD, 2019, 133 (01) :7-17

[7] Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel [J].

Doehner, Hartmut ;

Estey, Elihu ;

Grimwade, David ;

Amadori, Sergio ;

Appelbaum, Frederick R. ;

Buechner, Thomas ;

Dombret, Herve ;

Ebert, Benjamin L. ;

Fenaux, Pierre ;

Larson, Richard A. ;

Levine, Ross L. ;

Lo-Coco, Francesco ;

Naoe, Tomoki ;

Niederwieser, Dietger ;

Ossenkoppele, Gert J. ;

Sanz, Miguel ;

Sierra, Jorge ;

Tallman, Martin S. ;

Tien, Hwei-Fang ;

Wei, Andrew H. ;

Lowenberg, Bob ;

Bloomfield, Clara D. .

BLOOD, 2017, 129 (04) :424-447

[8] Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation [J].

Fang, Min ;

Storer, Barry ;

Wood, Brent ;

Gyurkocza, Boglarka ;

Sandmaier, Brenda M. ;

Appelbaum, Frederick R. .

CANCER, 2012, 118 (09) :2411-2419

[9] Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia [J].

Freeman, Sylvie D. ;

Virgo, Paul ;

Couzens, Steve ;

Grimwade, David ;

Russell, Nigel ;

Hills, Robert K. ;

Burnett, Alan K. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (32) :4123-+

[10]

Grimwade D, 2014, BLOOD, V124, P3345, DOI [10.1182/blood-2014-05-577593, 10.1182/asheducation-2014.1.222]

← 1 2 3 4 5 →